FDA Approves Pfizer's Anti-Smoking Drug Chantix™
Filed in archive Drugs, Vaccines and Therapeutics by ruth on May 11, 2006

The second nicotine free smoking-cessation drug has just been approved by the FDA. Varenicline, marketed
as Chantix, is marketed by Pfizer Inc. and is supposed to be taken twice daily for 12 weeks. How does it work?
Varenicline latches on to the same receptors in the brain that nicotine binds to when inhaled in cigarette smoke, an action that leads to the release of dopamine in the pleasure centers of the brain. Taking the drug blocks any inhaled nicotine from reinforcing that effect.
The drug also slows the release of dopamine, which cuts the craving to smoke that occurs when nicotine's effect wears off, said Pfizer research chemist Jotham Coe, who invented the drug.
Pfizer hopes to get the drug out in the market later his year, and has also applied for EU regulatory approval. Analysts say this could have the making of a blockbuster drug, possibly netting $500 million in annual sales by 2009.
Read more from AP via Mercury News. MSNBC has more, which also points out that the success of Chantix depends on medical insurance schemes, and whether it would be considered as preventative medicine.
Permalink: FDA Approves Pfizer's Anti-Smoking Drug Chantix™
Tags:
nicotine smoking biotech drug pfizer approves+pfizer drug+chantixâ„¢ smoking+drug
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/21886






